Trade Ligand Pharmaceuticals Incorpor - LGND CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.76 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 111.74 |
| Open | 111.62 |
| 1-Year Change | 54.15% |
| Day's Range | 111.62 - 117.32 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 21, 2025 | 117.32 | 5.40 | 4.82% | 111.92 | 117.32 | 109.91 |
| Jan 17, 2025 | 111.53 | 4.00 | 3.72% | 107.53 | 112.91 | 107.53 |
| Jan 16, 2025 | 110.68 | 2.62 | 2.42% | 108.06 | 112.04 | 107.63 |
| Jan 15, 2025 | 109.59 | 0.87 | 0.80% | 108.72 | 110.59 | 107.60 |
| Jan 14, 2025 | 108.11 | 2.35 | 2.22% | 105.76 | 108.39 | 103.51 |
| Jan 13, 2025 | 104.88 | 2.34 | 2.28% | 102.54 | 105.63 | 101.36 |
| Jan 10, 2025 | 106.21 | -2.42 | -2.23% | 108.63 | 108.63 | 103.78 |
| Jan 8, 2025 | 110.50 | 3.22 | 3.00% | 107.28 | 110.65 | 106.39 |
| Jan 7, 2025 | 110.12 | 5.21 | 4.97% | 104.91 | 110.81 | 104.91 |
| Jan 6, 2025 | 106.96 | -1.34 | -1.24% | 108.30 | 111.69 | 106.91 |
| Jan 3, 2025 | 110.21 | 2.69 | 2.50% | 107.52 | 110.59 | 106.13 |
| Jan 2, 2025 | 107.64 | 3.11 | 2.98% | 104.53 | 110.52 | 104.53 |
| Dec 31, 2024 | 105.86 | 0.82 | 0.78% | 105.04 | 107.32 | 104.71 |
| Dec 30, 2024 | 104.85 | 0.05 | 0.05% | 104.80 | 107.70 | 104.80 |
| Dec 27, 2024 | 108.26 | -4.44 | -3.94% | 112.70 | 112.70 | 107.88 |
| Dec 26, 2024 | 114.04 | 2.56 | 2.30% | 111.48 | 114.18 | 110.53 |
| Dec 24, 2024 | 112.61 | 0.91 | 0.81% | 111.70 | 114.01 | 111.21 |
| Dec 23, 2024 | 112.77 | 1.24 | 1.11% | 111.53 | 117.20 | 111.53 |
| Dec 20, 2024 | 113.67 | 3.16 | 2.86% | 110.51 | 115.53 | 108.36 |
| Dec 19, 2024 | 113.21 | -1.30 | -1.14% | 114.51 | 115.18 | 111.82 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Ligand Pharmaceuticals Incorpor Company profile
About Ligand Pharmaceuticals Inc.
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company. The Company is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. It has partnerships and license agreements with approximately 140 pharmaceutical and biotechnology companies and 400 programs are in various stages of commercialization, development or research and are fully funded by its collaboration partners and licensees. Its technologies include OmniAb Technologies, Pelican Expression Technology Platform, Captisol Technology, HepDirect, LTP, BEPro Technology Platform, and SUREtechnology Platform. The OmniAb platform creates and screens diverse antibody pools and is designed to identify optimal antibodies. The Pelican Expression Technology is a scalable platform for recombinant protein production and is suited for complex, large-scale protein production. Captisol is a chemically modified cyclodextrin designed to optimize the stability of drugs.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Ligand Pharmaceuticals Inc. revenues increased 49% to $277.1M. Net income totaled $57.1M vs. loss of $3M. Revenues reflect Captisol segment increase of 49% to $164.3M, Milestone segment increase from $11.5M to $28.7M. Net Income reflects Gain (loss) from short-term investments decrease of 76% to $4M (expense), Other General and administrative decrease of 23% to $36.1M (expense).
Equity composition
Common Stock $.006 Par, 3/11, 33,333,3333 auth., 20,644,234 issd., less 1,118,222 shs in Treas. @ $42.3M. Insiders own 3.36%. IPO:11/92, 4.3M Class A shares @ $11 by Lehman Bros. FY'00 Q's are restated for SAB 101 adjustment. 9/05,Co. delisted from NASDAQ to OTC.11/10, 1-for-06 Reverse Stock split.
| Industry: | Pharmaceuticals (NEC) |
3911 Sorrento Valley Blvd
Suite 110
SAN DIEGO
CALIFORNIA 92121
US
News
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024People also watch
Still looking for a broker you can trust?
Join the 680,000+ traders worldwide that chose to trade with Capital.com